Navigation Links
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors.

The data (Abstract #380), which were presented today at the annual meeting of the American Society of Gene Therapy, showed that in this 22-patient trial, INGN 241 induced killing in all treated tumors, including in those patients who failed prior therapy with other anti-cancer agents. INGN 241 was well tolerated, and a maximum tolerated dose was not reached. Tumor growth control was observed in 44 percent of treated tumors. Two of five patients treated at the highest dose showed objective responses (greater than 50 percent reduction in tumor size). Increases in the number of immune cells known to mediate anti-tumor effects were also observed in all patients, consistent with the immune-stimulating activity of INGN 241.

Although INGN 241 was administered directly to tumors, evidence of distant biologic activity was observed, suggesting that this therapy may have utility in treating primary tumors as well as metastatic disease. INGN 241 treatment in combination with radiotherapy is being evaluated in an ongoing Phase 3 trial in solid tumors, including patients with head and neck cancer.

"These data are particularly encouraging because they demonstrate INGN 241 has clinical activity even in patients who have failed previous therapies," said Sunil Chada, Ph.D., associate vice president, Clinical Research and Development at Introgen.

INGN 241 Shown to Restore Platinum Sensitivity in Preclinical Studies

Data from preclinical studies of INGN 241 also were presented (Abstract #197) that evaluated the ability of INGN 241 to restore cisplatin sensitivity to ovarian cancer cells that are cisplatin-resistant. The results showed that INGN 241 effecti
'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:10/20/2014)... Oct. 20, 2014  BioPontis Alliance for Rare ... philanthropies, announced today the creation of a joint ... of the rare disease known as Charcot- Marie-Tooth ... alliance model earlier this month. Today,s partnership announcement ... collaborative model where researchers and all CMT dedicated ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:10/19/2014)... October 19, 2014 Große ... Das Problem dabei ist, dass große Pharmafirmen ... Kompetenz zu teilen. Es war deshalb ... wir uns umso mehr, dass es uns gelungen ... bei Kühlketten aufzuschreiben - mit einem Vorbehalt - ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... its entry into the Omaha market today with ... new stores in the city of Omaha.  Joining ... Jim Suttle, Mayor of Omaha and City Councilmember ... http://www.newscom.com/cgi-bin/prnh/20100816/NE50800LOGO) Omaha is the latest market ...
... 16 PLC Systems Inc. (OTC Bulletin Board: ... medical device-based technologies, today reported financial results for the three- ... Second quarter 2010 total revenues were $1,019,000, a decrease ... a decrease of $43,000 from $1,062,000 reported in the first ...
Cached Medicine Technology:CVS/pharmacy Enters Omaha Market 2PLC Systems Reports Second Quarter 2010 Results 2PLC Systems Reports Second Quarter 2010 Results 3PLC Systems Reports Second Quarter 2010 Results 4PLC Systems Reports Second Quarter 2010 Results 5
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that ... announced its latest designs of 2014 mother of ... elegant outfits are offered with big discounts, up to ... October 30 can enjoy this special offer. , ... it has become one of the leading brands in ...
(Date:10/19/2014)... Visual Impact Frequency Training - ... released to the public generating a frenzied buzz ... fitness community. The commotion surrounding the program's launch ... prompting an investigative review. , "Many gym-goers are ... commonly known as a training 'plateau' where they ...
(Date:10/19/2014)... New stem cell-based research could improve understanding of intestinal ... study suggests. Scientists used stem cells to grow ... dish. They then transplanted the organoids into mice, creating ... the researchers. "This provides a new way to ... intestinal failure, from genetic disorders appearing at birth to ...
(Date:10/19/2014)... The U.S. Government has initiated a major effort ... 2025. However, a workgroup of nearly 40 Alzheimer,s ... the U.S. Government,s National Plan to Address Alzheimer,s ... scale, and adequately funded in order to successfully ... the workgroup to enlarge and strengthen the Plan ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... Patients are urged,to suggest candidates for ... participation is vital; many past award winners ... sponsored by the Pennsylvania Academy of Family,Physicians ... provides compassionate, comprehensive care. Eligible nominees must ...
... 16 Americans consume more calories as a,nation on Super ... save,Thanksgiving. By the time the final whistle blows at Super ... greasy pizza,fried chicken wings, and beer., But this year ... of the,football field 109 times to burn off all of ...
... at the Johns Hopkins Brady Urological Institute, Wake Forest University ... of gene markers for hereditary prostate cancer that, along with ... more than nine times that of men without such markers. ... 4,000 Swedes, found that these markers are common and could ...
... history can increase risk up to tenfold, study suggests, , , ... that looks at five genetic variants could one day predict ... , Researchers found that among men with four of the ... percent to 500 percent, compared to men with none of ...
... prevention experts from the University of North Carolina at ... Medicine and Duke University Medical Center will undertake a ... project, the largest and most comprehensive in the country, ... Prevention, the Doris Duke Charitable Foundation and The Duke ...
... cells in the lungs of patients diagnosed with ... death, University of Cincinnati (UC) researchers have discovered. ... of neutrophil (pronounced new-tro-fil) cellsa type of white ... 30 percent increased risk of mortality in the ...
Cached Medicine News:Health News:Nominate Your Family Doctor for Family Physician of the Year 2Health News:Eat This, Not That!(TM): 5 Smart Super Bowl Swaps That Will Save You Hundreds of Calories 2Health News:Gene markers located for hereditary prostate cancer 2Health News:Gene markers located for hereditary prostate cancer 3Health News:Genetic Mutations Boost Prostate Cancer Risk 2Health News:Genetic Mutations Boost Prostate Cancer Risk 3Health News:UNC, Duke lead first statewide shaken baby prevention research project in US 2Health News:UNC, Duke lead first statewide shaken baby prevention research project in US 3Health News:UNC, Duke lead first statewide shaken baby prevention research project in US 4Health News:Rare lung disease cells indicate higher death risk 2
... benefits from innovative research in materials and ... as the aerospace and automotive industry, the ... the footwear and textile industry. , ,This ... the Carrera sunglasses collection to create unique ...
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
The latest VALENTINO eyewear collection is a refined expression of sophisticated luxury,balancing ultimate feminine, chic styles against understated, minimalist mens models....
Medicine Products: